Participated · Series A · Jul 2026

Proxima Fusion is Europe’s leading stellarator company and the first spin-out from the Max Planck Institute for Plasma Physics, developing commercial fusion power plants using the QI-HTS stellarator concept. The company is building Alpha, a net-energy stellarator demonstrator targeted for the early 2030s, and plans a follow-on commercial plant called Stellaris later in the decade. Proxima leads the Alpha project in partnership with the state of Bavaria, the Max Planck Institute for Plasma Physics and industrial partners including RWE, supported by an Alpha Alliance of more than 50 companies. Headquartered in Munich with offices in Zurich and Oxford, Proxima employs around 200 people across engineering, science and operations. Financially, Proxima has secured more than €650 million in funding to date, including about €95 million in public grants, and plans to expand engineering, manufacturing and magnet production capabilities as it advances toward demonstrator completion.

Participated · Series D · Jun 2026

Isar Aerospace develops the Spectrum small-satellite orbital launch vehicle and positions itself as a commercial launch provider. Founded in 2018 in Munich, the company operates a 40,000 square metre production facility in Parsdorf designed to produce up to 40 Spectrum rockets per year, with vehicles three through seven already in production. Its launch manifest is booked through 2028 with customers including ESA, NOSA, ElevationSpace and Astroscale, and it operates from Andøya with a second launch site secured in Canada (Spaceport Nova Scotia). The company has pursued industrial partnerships such as a cooperation agreement with TKMS and received institutional backing including a €65 million NATO Innovation Fund extension in 2024. Spectrum’s qualification flight window opened June 15–21 after an initial March 30, 2025 launch that lasted under 30 seconds and several subsequent aborted attempts; reaching orbit is a milestone that would establish Isar as a commercial provider. With the recent financing, total funding across equity and debt is about €870 million, and capital is being directed at production scale-up, launch infrastructure, and executing its booked manifest.

Participated · Equity · Feb 2026

Founded in 2014, GVG Glasfaser develops, owns, and operates fiber-to-the-home networks, enabling high-speed internet access for residential and enterprise customers nationwide. The company reported a 70 % year-over-year increase in activated customers in the last fiscal year and now supplies more than 180,000 households and companies with fiber connectivity. Management is concentrating on ‘homes activated’ rather than ‘homes passed’, reflecting a sector-wide shift toward monetized connections. Robust, contractually secured cash flows and disciplined network roll-outs have helped the firm attract fresh funding despite a challenging market marked by high construction and financing costs. Current private-equity backer Palladio Partners continues to hold its ownership stake. The newly secured capital will support further nationwide expansion of the fiber network, positioning the company for continued customer and revenue growth.

Participated · Seed · Aug 2025

paddy is an AI platform that automates lesson planning, content creation, and class-performance analysis to reduce teachers' administrative workload. The product generates differentiated materials, suggests tasks and methods, and identifies students who need extra support. Founded in 2024 as DigitalErleben GmbH and launched in January 2025, the startup was created by three founders who grew up in teaching households. The platform reached 12,000 teacher users and 100 school customers within six months of launch. Management says lesson preparation is the most-used feature and plans to improve in-class teaching capabilities next. The company is hiring aggressively and expects to reach 500 school customers next year and mid-six-figure revenue by year-end.

Participated · Series B · Apr 2024

CryoTherapeutics has developed an intravascular catheter system that delivers cryoenergy at approximately –10° to –20°C via a console-controlled cooling agent to stabilise high-risk coronary plaque and potentially prevent heart attacks. The company has completed first-in-human studies with follow-up and reports promising early data on safety and feasibility. CoreAlst served as the corelab involved in analysis of the clinical data, and the firm plans to present early human results at CRT in Washington DC and at EuroPCR in Paris. Proceeds from its recent fundraise will support additional clinical evaluation of the technology and the development of a next-generation catheter system for advanced clinical studies and early commercialisation. CryoTherapeutics said it will also use funding to expand its team in Liège. The company was founded by John Yianni, who is a board member of several medical device companies and a partner at Earlybird Venture Capital Health Fund. CryoTherapeutics develops a proprietary intravascular cryotherapy catheter that delivers sub-zero temperatures at its tip to treat inflamed areas of the coronary artery and stabilise atherosclerotic lesions. The company is focused on demonstrating clinical benefit and early-stage commercialization of this cryo-energy technology in cardiovascular disease. It plans to leverage recent imaging breakthroughs to target vulnerable plaques and is commencing its first clinical study focused on treating this disease. Proceeds from the latest financing will fund that clinical study and support development of a next-generation cryotherapy system aimed at commercial launch. The company also intends to expand its team and local partnerships in the Walloon region as it advances development. CryoTherapeutics was established in December 2009 in Germany and located in Awans (Liège) in 2019. CryoTherapeutics develops a proprietary cryotherapy system—an intravascular catheter that delivers sub-zero temperatures at its tip to treat inflamed areas of the coronary artery. The technology aims to stabilize lesions that might rupture and cause heart attacks, positioning the product for treatment of coronary artery disease. The company is focused on development, demonstration of clinical benefit, and early-stage commercialization. It intends to use the €7m Series B funds for clinical activities, further R&D, talent acquisition, international growth and to establish operations at a new facility in Awans, Belgium. Financing came as a mix of equity, debt and grants, including non-dilutive cash advances from the Walloon region (DG06); investors include Noshaq, Peppermint Venture Partners, Creathor Ventures and Getz Brothers. CryoTherapeutics was established in December 2009 and is led by CEO John Yianni. CryoTherapeutics is developing a proprietary cryotherapy system delivered via catheter for treatment of coronary artery disease, including acute coronary syndromes and myocardial infarction. The approach aims in many patients to avoid the use of intravascular stents or scaffolds, thereby maintaining vascular function in the treated vessel. The company intends to advance its catheter-based system into a clinical trial with the goal of achieving CE-mark market approval in Europe. In July 2016 it raised €5.2m in a Series B financing to support that clinical development. The round was led by Creathor Venture and included existing investors. CryoTherapeutics was established in December 2009 by Dr. John Yianni (CEO) and Dr. Maurice Buchbinder (CMO) and is based in Potsdam, Germany. CryoTherapeutics develops a proprietary catheter-based cryotherapy system intended to treat coronary artery disease and prevent heart attacks. The system uses cryoenergy and is designed for use by interventional cardiologists during acute care. The company's initial objective is to demonstrate the clinical benefit of the catheter-based approach in treating heart attack patients. CryoTherapeutics completed an extension to its Series A financing, bringing the total of the round to €6.5m. Established in December 2009 and based in Cologne, Germany, the company is advancing its device toward clinical demonstration. Management is led by Maurice Buchbinder, MD, Chief Medical Officer, and John Yianni, PhD, Managing Director.